Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity
Citation
Javitt, J. C., Zlateva, G. P., Earnshaw, S., Pleil, A. M., Graham, C., Brogan, A., ... Adamis, A. R. (2008). Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity. Value in Health, 11(4), 563-574.